ArticlePloS one2015

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Sarah L Larsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.